LB Pharmaceuticals Inc (LBRX)Healthcare | Biotechnology | New York, United States | NasdaqGM
47.73 USD
-0.16
(-0.334%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 47.73 |
Hot Take ↕ | Aug. 22, 2026, 4:51 a.m. EDT
The immediate outlook is mixed but leans cautiously bullish due to strong technical momentum. The stock has rallied significantly off its lows, trading well above both its 50-day and 200-day averages, suggesting institutional accumulation. However, this optimism clashes violently with the company's fundamental reality: it is burning cash, reporting negative earnings, and has no dividend to speak of. The massive put option activity suggests retail investors are hedging against a potential reversal of this rally, fearing the 'value trap' narrative will reassert itself if clinical trial results in 2027 do not materialize. While the technical setup supports a short-term pop, the lack of profitability and negative free cash flow makes this a speculative gamble rather than a sound investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.095909 |
| AutoETS | 0.144549 |
| AutoARIMA | 0.144625 |
| MSTL | 0.147319 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 53.32 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 1.35 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.57 |
| Market Cap | 1,539,730,432 |
| Forward P/E | -9.48 |
| Previous Name | WhiteBIT Token |
| Website | https://lbpharma.us |
As of Aug. 22, 2026, 4:51 a.m. EDT: Speculators are heavily positioning for downside protection, with significant open interest in out-of-the-money puts expiring in late October and January 2027. Call activity is sparse and concentrated near the money, while put volume far exceeds call volume at lower strikes, indicating a bearish sentiment despite recent price gains.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.768208 |
| Address1 | One Pennsylvania Plaza |
| Address2 | Suite 1025 |
| All Time High | 50.16 |
| All Time Low | 13.36 |
| Ask | 57.43 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 265,060 |
| Average Daily Volume3 Month | 327,300 |
| Average Volume | 327,300 |
| Average Volume10Days | 265,060 |
| Bid | 32.42 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 11.588 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 47.73 |
| Current Ratio | 15.078 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 49.245 |
| Day Low | 46.37 |
| Debt To Equity | 1.57 |
| Display Name | LB Pharmaceuticals |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -91,030,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -13.371 |
| Enterprise Value | 1,217,157,376 |
| Eps Current Year | -5.54167 |
| Eps Forward | -5.03571 |
| Eps Trailing Twelve Months | -5.1 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 38.3843 |
| Fifty Day Average Change | 9.345699 |
| Fifty Day Average Change Percent | 0.24347714 |
| Fifty Two Week Change Percent | 176.8208 |
| Fifty Two Week High | 50.16 |
| Fifty Two Week High Change | -2.4300003 |
| Fifty Two Week High Change Percent | -0.048444983 |
| Fifty Two Week Low | 13.36 |
| Fifty Two Week Low Change | 34.37 |
| Fifty Two Week Low Change Percent | 2.572605 |
| Fifty Two Week Range | 13.36 - 50.16 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,757,597,400,000 |
| Float Shares | 26,460,266 |
| Forward Eps | -5.03571 |
| Forward P E | -9.478306 |
| Free Cashflow | -53,921,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 49 |
| Fullday Change | -0.16 |
| Fullday Change Percent | -0.334099 |
| Fullday Price | 47.73 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0023999999 |
| Held Percent Institutions | 1.01373 |
| Implied Shares Outstanding | 32,259,175 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-09-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York. |
| Long Name | LB Pharmaceuticals Inc |
| Market | us_market |
| Market Cap | 1,539,730,432 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_413161432 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -85,685,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,544,891,890 |
| Number Of Analyst Opinions | 8 |
| Open | 47.64 |
| Operating Cashflow | -82,395,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 212 605 0300 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 47.73 |
| Post Market Time | 1,787,959,805 |
| Prev Name | WhiteBIT Token |
| Previous Close | 47.89 |
| Price Eps Current Year | -8.612927 |
| Price Hint | 2 |
| Price To Book | 4.118916 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.911 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.125 |
| Region | US |
| Regular Market Change | -0.16 |
| Regular Market Change Percent | -0.334099 |
| Regular Market Day High | 49.245 |
| Regular Market Day Low | 46.37 |
| Regular Market Day Range | 46.37 - 49.245 |
| Regular Market Open | 47.64 |
| Regular Market Previous Close | 47.89 |
| Regular Market Price | 47.73 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 230,558 |
| Return On Assets | -0.29983 |
| Return On Equity | -0.50001 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 32,259,175 |
| Shares Percent Shares Out | 0.1598 |
| Shares Short | 5,156,413 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,260,793 |
| Short Name | LB Pharmaceuticals Inc |
| Short Percent Of Float | 0.1881 |
| Short Ratio | 13.65 |
| Source Interval | 15 |
| State | NY |
| Symbol | LBRX |
| Target High Price | 78.0 |
| Target Low Price | 37.0 |
| Target Mean Price | 53.375 |
| Target Median Price | 53.5 |
| Total Cash | 327,790,016 |
| Total Cash Per Share | 10.161 |
| Total Debt | 5,217,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.1 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 27.710175 |
| Two Hundred Day Average Change | 20.019825 |
| Two Hundred Day Average Change Percent | 0.722472 |
| Type Disp | Equity |
| Volume | 230,558 |
| Website | https://lbpharma.us |
| Zip | 10,119 |